Neurogene (NASDAQ:NGNE) Stock Gets Price Target Cut from HC Wainwright

Neurogene (NASDAQ:NGNE) had its price objective decreased by HC Wainwright from $65.00 to $60.00 in a research report sent to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Neurogene’s Q4 2026 earnings at ($1.16) EPS, FY2026 earnings at ($5.04) EPS, Q1 2027 earnings at ($1.18) EPS, Q2 2027 earnings at ($1.19) EPS, Q3 2027 earnings at ($1.21) EPS, Q4 2027 earnings at ($1.22) EPS and FY2027 earnings at ($4.80) EPS.

Several other equities analysts also recently weighed in on the company. Canaccord Genuity Group reduced their price target on Neurogene from $180.00 to $166.00 and set a “buy” rating for the company in a report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a research note on Thursday, October 15th. Guggenheim upped their price target on shares of Neurogene from $69.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. William Blair raised shares of Neurogene to a “strong-buy” rating in a research report on Wednesday, September 23rd. Finally, JPMorgan Chase & Co. assumed coverage on shares of Neurogene in a research report on Thursday, October 8th. They set an “overweight” rating and a $60.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $79.57.

Neurogene Price Performance

Shares of NGNE opened at $23.90 on Tuesday. The business’s 50 day moving average price is $28.49 and its 200-day moving average price is $28.06. Neurogene has a 52 week low of $15.93 and a 52 week high of $43.66.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings data on Monday, November 9th. The company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.31. On average, analysts forecast that Neurogene will post -5.26 EPS for the current year.

Institutional Trading of Neurogene

A number of large investors have recently made changes to their positions in the stock. State Street Corp raised its holdings in shares of Neurogene by 22.4% during the third quarter. State Street Corp now owns 549,269 shares of the company’s stock valued at $15,281,000 after purchasing an additional 100,625 shares during the last quarter. Keybank National Association OH bought a new position in Neurogene during the third quarter valued at approximately $221,000. Alps Advisors Inc. lifted its position in Neurogene by 65.4% during the third quarter. Alps Advisors Inc. now owns 26,528 shares of the company’s stock valued at $738,000 after purchasing an additional 10,488 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Neurogene in the third quarter worth approximately $28,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Neurogene by 45.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,651 shares of the company’s stock worth $104,000 after purchasing an additional 1,136 shares during the last quarter. 52.37% of the stock is currently owned by institutional investors.

Key Neurogene News

Investors following NGNE have been watching these news items:

• Positive Sentiment: HC Wainwright raised its EPS estimates for FY2026 and FY2027 and for each reported quarter from Q4 2026 through Q4 2027, projecting smaller losses than before. The firm maintained its Buy rating and $60 price target. HC Wainwright forecast report
• Positive Sentiment: Canaccord Genuity also kept its Buy rating on Neurogene, reinforcing the positive analyst stance. Canaccord rating update
• Neutral Sentiment: A Zacks analysis cited an average analyst price target implying substantial potential upside, while cautioning that price-target projections are not necessarily reliable. Zacks analyst price-target analysis

About Neurogene

Neurogene Inc. is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. Its work focuses on using gene therapy to address the underlying causes of disorders with limited treatment options. The company’s lead program, NGN-401, is an investigational gene therapy for Rett syndrome, a rare genetic disorder that primarily affects girls and can cause significant developmental and neurological challenges. Neurogene is also advancing a broader pipeline of potential genetic medicines for rare diseases.